The impact of sphingosine-1-phosphate receptor modulators on COVID-19 and SARS-CoV-2 vaccination

SARS‐CoV‐2 vaccination and infection in ozanimod‐treated participants with relapsing multiple sclerosis

“…15,21,32,[36][37][38] Differences in seroconversion rates between fingolimod and ozanimod may be due to variations in the assays used between studies or may be a result of differences in S1P receptor specificity, effects on influencing the adaptive immune system, or patient backgrounds with respect to prior treatment exposures or other host factors. 38,39 In addition, assays vary in terms of sensitivity to detect prior infection and in the durability of measured responses, leading to discrepancies between data sets. 40 In ozanimod-treated participants who received an mRNA vaccine, the spike RBD antibody levels observed in this analysis ranged from approximately 1.3 U/mL (in participants with no serologic evidence of SARS-CoV-2 exposure) to 44,260 U/mL (in participants with serologic evidence of SARS-CoV-2 exposure).…”

“…The high rate (100%) of seroconversion in ozanimod‐treated participants with RMS after SARS‐CoV‐2 mRNA vaccination contrasts with data that observed failure to develop a postvaccination humoral response in fingolimod‐treated patients with MS fully vaccinated against SARS‐CoV‐2 with the Pfizer vaccine (determined with EUROIMMUN anti‐SARS‐CoV‐2 IgG quantitative ELISA assay/AGILITY ELISA analyzer [DYNEX]) 8 . Although the number of studies reporting the impact of S1P receptor modulators on SARS‐CoV‐2 vaccination is relatively small at this time, data currently suggest that seroconversion rates are generally higher in patients treated with ozanimod (84%–100%) than fingolimod (28%–77%) 15,21,32,36–38 . Differences in seroconversion rates between fingolimod and ozanimod may be due to variations in the assays used between studies or may be a result of differences in S1P receptor specificity, effects on influencing the adaptive immune system, or patient backgrounds with respect to prior treatment exposures or other host factors 38,39 .…”

Update des Addendums zu den S3-Leitlinien Morbus Crohn und Colitis ulcerosa: Betreuung von Patienten mit chronisch-entzündlichen Darmerkrankungen in Bezug auf COVID-19 (Version 2.0)

“…Daher kann keine Aussage über den Einfluss auf die SARS-COV 2-Infektion bei Patientinnen und Patienten mit CED gemacht werden. Bei Patientinnen und Patienten mit Multipler Sklerose, die mit S1P-Modulatoren behandelt wurden (vornehmlich Fingolimod), wurde hingegen keine Assoziation mit einem schweren Erkrankungsverlauf beobachtet [87].…”

Sphingosine 1‐phosphate receptor modulators in multiple sclerosis treatment: A practical review

“…61 However, severe disease and mortality in patients treated with all four S1P receptor modulators were comparable to the general population. 35,62,63 Some studies demonstrated that patients with MS treated with S1P receptor modulators, particularly fingolimod, may have limited ability to develop a humoral immune response after COVID-19 vaccination. [64][65][66][67][68] Fingolimod-, ponesimod-, or siponimod-treated patients were seropositive after second and third mRNA vaccinations, but with lower immunoglobulin G levels compared with untreated patients.…”

“…Considering the reduction in lymphocyte count observed with S1P receptor modulator treatment, it was initially thought that patients with MS undergoing treatment may be more susceptible to poor outcomes from COVID‐19 61 . However, severe disease and mortality in patients treated with all four S1P receptor modulators were comparable to the general population 35,62,63 …”